dem10/E+ via Getty Images I see a similar pattern to what happened nearly a year ago during Trump's tariff sell-off. However, I am not buying the dip yet despite the fundamentals of the high-growth pockets in the market (mainly beneficiaries from the AI data center buildout) remaining intact. Trying to time the bottom of a selloff is often a sucker's bet, but I'm more than happy to take this one. ...
dem10/E+ via Getty Images I see a similar pattern to what happened nearly a year ago during Trump's tariff sell-off. However, I am not buying the dip yet despite the fundamentals of the high-growth pockets in the market (mainly beneficiaries from the AI data center buildout) remaining intact. Trying to time the bottom of a selloff is often a sucker's bet, but I'm more than happy to take this one. Why? So far, I am not seeing any signs of capitulation. Since the war began, the SPY hasn't seen a single 2% drop in one day. Let alone a 4% drop like in April last year. On top of that, the S&P 500 is still in a very awkward place right now from a technical perspective, with poor breadth in pretty much all sectors except energy. Guidance Terminal | Market breadth and returns across all 11 sectors | 1-month timeframe In this piece, I will focus on the most recent data that tries to put a number on the global impact of higher oil prices due to the conflicts in the Middle East. My view is that this data is overly pessimistic. The U.S. consumer is starting to sweat about higher-for-longer gas prices, although I take the survey data with skepticism. Overall, I am staying on the sidelines, as I don't think the lows are behind us. I still see the SPY at $610-$620 in the first half of the year, followed by a rally in the second half, as the oil shock fades (similarly to the tariff fears last year). This is an exogenous event, and I strongly believe it will be transitory, even though "experts" suggest otherwise. I discuss more below. OECD Cuts the Quality of Its Global Outlook The Organisation for Economic Co-operation and Development released its interim report last Thursday, showing a 1.2 percentage point increase in inflation to 4.0% for G20 countries this year. OECD The reason I'm highlighting this report is that it's the first main study since the war that tries to quantify the impact of higher for longer oil prices due to the Strait of Hormuz being blocked. Notably, this orga...
EschCollection/DigitalVision via Getty Images Healthcare diagnostics has been one of my favorite industries to cover, but they have been dealing with macroeconomic headwinds, pricing pressures from payers, and scrutiny over reimbursement. As a result, many of my healthcare diagnostic stocks are struggling to make gains, even as these companies continue to report clinical and commercial progress. T...
EschCollection/DigitalVision via Getty Images Healthcare diagnostics has been one of my favorite industries to cover, but they have been dealing with macroeconomic headwinds, pricing pressures from payers, and scrutiny over reimbursement. As a result, many of my healthcare diagnostic stocks are struggling to make gains, even as these companies continue to report clinical and commercial progress. The market’s neglect has produced some intriguing opportunities to invest in companies that have significant clinical power but also offer scalable business models. Castle Biosciences, Inc. ( CSTL ) is currently showing an opportunity as a leader in precision diagnostics for a variety of cancer diagnostics, including their melanoma product, DecisionDx-Melanoma. The company is set to present updated data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, showing that their DecisionDx-Melanoma test can help stratify mortality risk within AJCC stages for patients with cutaneous melanoma (CM). Although this data presentation might not be a catalyst for the stock, I’m more interested that the company has the evidence to show that DecisionDx-Melanoma enables personalized care for patients and providers, while commercially, we could still see additional adoption, which would help revitalize the share price. As a result, I’m looking to start a pilot position in the immediate term and will look to build a position over the course of 2026 as the company invests in growth. I intend to provide a brief background on Castle Biosciences and their current performance. Then, I will discuss why I’m bullish on DecisionDx-Melanoma and why I’m looking for entry in the immediate term. I will also point out some downside risks that investors need to consider when managing their CSTL position. Finally, I take a look at CSTL’s daily chart to see if I can identify an entry point. Background on Castle Biosciences Castle Biosciences offers patient-centered genomic and molecular tests to ...
Annexon Biosciences press release ( ANNX ): Q4 GAAP EPS of -$0.28 beats by $0.04 . Cash, cash equivalents and short-term investments were $238.3 million as of December 31, 2025, including $86.3 million in gross proceeds from a November 2025 public offering. Based on focused investments in its lead late-stage programs, Annexon expects to fund operations and anticipated milestones into the second ha...
Annexon Biosciences press release ( ANNX ): Q4 GAAP EPS of -$0.28 beats by $0.04 . Cash, cash equivalents and short-term investments were $238.3 million as of December 31, 2025, including $86.3 million in gross proceeds from a November 2025 public offering. Based on focused investments in its lead late-stage programs, Annexon expects to fund operations and anticipated milestones into the second half of 2027. More on Annexon Biosciences Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER Trials - Slideshow Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER Trials Transcript Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences
Douglas Rissing "The current stance of monetary policy is well positioned to balance the risks to our maximum employment and price stability goals," said John Williams, a permanent member of the Federal Open Market Committee. The president of the Federal Reserve Bank of New York participated in a conversation at an event organized by the Staten Island Economic Development Corporation. "Despite hei...
Douglas Rissing "The current stance of monetary policy is well positioned to balance the risks to our maximum employment and price stability goals," said John Williams, a permanent member of the Federal Open Market Committee. The president of the Federal Reserve Bank of New York participated in a conversation at an event organized by the Staten Island Economic Development Corporation. "Despite heightened uncertainty around the impact of trade and other policies, the economy has been resilient, with growth remaining solid through last year and into the beginning of this year," said Williams. "Consumer spending has been resilient, and business investment has been strong. And the unemployment rate has stabilized over recent months. Inflation remains somewhat elevated due to the effects of tariffs, but those effects should begin to dissipate later this year," he added. Williams said it's an unusual time for the economy, with substantial risks and high uncertainty - particularly around the economic effects of the Middle East conflict. "In assessing the future path of monetary policy, my views, as always, will be based on the evolution of the totality of the data, the economic outlook, and the balance of risks to the achievement of our maximum employment and price stability goals," he said. Turning to one side of the Fed's dual mandate - maximum employment - "We are getting mixed signals, with some key indicators showing signs of steadying while others are suggesting a weakening labor market." The FOMC voting member mentioned a low-hire, low-fire environment in existence currently, and said, "The low hiring rate, along with an increase in long-term unemployment, may be contributing to a somewhat more pessimistic perception among households than other indicators of the labor market might suggest." For the other side of the Fed's mandate - price stability - "Inflation is experiencing its own unusual crosscurrents due to the effects of tariffs and developments in the Middle ...
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) ...
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial with AKY-2519 1 . AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in several solid tumor types including prostate and lung cancers, and is the second clinical stage miniprotein radioconjugate discovered using Aktis’ proprietary platform. The Company’s lead miniprotein radioconjugate, AKY-1189, targeting Nectin-4, is currently enrolling patients in a Phase 1b clinical study. Aktis’ miniprotein radioconjugates are designed to selectively deliver actinium-225 ( 225 Ac), a highly potent alpha-emitting radioisotope, to target-expressing tumors. The Company also provided business updates and reported financial results for the year ended December 31, 2025.
As the Big Tech selloff continues, some investors point to historical precedents as signals that this could be a buying opportunity. Denise Chisholm, Fidelity's director of quantitative market strategy, discusses the conditions with Tim Stenovec on “Bloomberg Tech.” (Source: Bloomberg)
As the Big Tech selloff continues, some investors point to historical precedents as signals that this could be a buying opportunity. Denise Chisholm, Fidelity's director of quantitative market strategy, discusses the conditions with Tim Stenovec on “Bloomberg Tech.” (Source: Bloomberg)
The following companies are expected to report earnings prior to market open on 03/31/2026. Visit our Earnings Calendar for a full list of expected earnings releases.McCormick & Company, Incorporated (MKC)is reporting for the quarter ending February 28, 2026. The food compan
The following companies are expected to report earnings prior to market open on 03/31/2026. Visit our Earnings Calendar for a full list of expected earnings releases.McCormick & Company, Incorporated (MKC)is reporting for the quarter ending February 28, 2026. The food compan
Federal Reserve Bank of New York President John Williams said interest rates were well positioned amid signs of significant supply chain disruptions due to war in the Middle East. “The conflict in the Middle East could result in a large supply shock with pronounced effects” that both boost price pressures but also dampen economic activity, he said. “This has begun to play out already,” Williams ad...
Federal Reserve Bank of New York President John Williams said interest rates were well positioned amid signs of significant supply chain disruptions due to war in the Middle East. “The conflict in the Middle East could result in a large supply shock with pronounced effects” that both boost price pressures but also dampen economic activity, he said. “This has begun to play out already,” Williams added, pointing to disruptions in the supply of energy and related goods. Yet Williams signaled the best response by the Fed, at least for now, was no response. “The current stance of monetary policy is well positioned to balance the risks to our maximum employment and price stability goals,” Williams said Monday in prepared remarks in an event organized by the Staten Island Economic Development Corporation. A spike in energy prices as a result of the war in Iran has raised new risks for both of the Fed’s policy goals. After holding interest rates steady earlier this month, some Fed officials are voicing fresh concerns about inflation while others favor a patient approach in assessing fallout from the now month-long war. “Uncertainty around the future path of inflation is high,” Williams said. He expects higher headline inflation in coming months driven by a significant increase in energy prices. But the move should partially reverse later this year, he said, assuming hostilities in the Middle East cease and prices come down. He forecasts inflation at the end of 2026 will be 2.75%. The New York Fed chief said he expects the economy will grow 2.5% this year, with tailwinds from fiscal policy, favorable financial conditions and investments in artificial intelligence. The labor market “has been sending an unusual set of mixed signals” but the unemployment rate should edge down amid higher growth, he said. Read More: Powell Says Longer-Term Inflation Expectations Remain in Check Earlier on Monday, Fed chair Jerome Powell said it was still too early to assess the economic impact o...